Lipoprotein(a), PCSK9 Inhibition, and Cardiovascular RiskMichelle L. O’Donoghue, Marc S. Sabatine|Circulation|2019Cited by 930
Prasugrel Compared With High Loading- and Maintenance-Dose Clopidogrel in Patients With Planned Percutaneous Coronary InterventionStephen D. Wiviott, Eugene Braunwald, Dietmar Trenk et al.|Circulation|2007Cited by 877
Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trialsMichelle L. O’Donoghue, Stephen D. Wiviott, Elliott M. Antman et al.|The Lancet|2009Cited by 723
Small Interfering RNA to Reduce Lipoprotein(a) in Cardiovascular DiseaseMichelle L. O’Donoghue, Marc S. Sabatine, Robert S. Rosenson et al.|New England Journal of Medicine|2022Cited by 513
2025 ACC/AHA/ACEP/NAEMSP/SCAI Guideline for the Management of Patients With Acute Coronary SyndromesSunil V. Rao, Frederick G.P. Welt, Michelle L. O’Donoghue et al.|Journal of the American College of Cardiology|2025Cited by 346